Alternatives to TrakGene: a 2026 field guide for clinical pedigree software

Looking for an alternative to TrakGene? Here's an honest field guide. TrakGene is a credible modern clinical genetics platform — clinician-built, HL7 FHIR-first, with public customers including NIH, NHS services, and Geisinger. Most teams who reach this page are not dissatisfied with TrakGene as a clinical product; they are usually evaluating it alongside one or two modern peers, or looking for AI-assisted interpretation, richer cancer-risk modelling, or a lower-friction procurement path before making a decision.

This page covers four serious alternatives — Phenotips, FamGenix, Progeny, and Evagene — and tells you plainly where each fits and where each falls short. Evagene publishes this site; we mark its limitations (cancer-risk breadth against FamGenix, HPO against Phenotips) as plainly as we mark its strengths.

Short version. If deep phenotype-driven rare disease diagnostics are central, Phenotips. If cancer-risk breadth (BOADICEA v6, Tyrer-Cuzick v8, Gail, Claus, QRISK3) is central, FamGenix. If you want continuity with a long-established enterprise vendor, Progeny. If you want a modern peer to TrakGene with educational HPO phenotyping, an educational/research relatedness module, AI-assisted draft summaries, an MCP server, Analysis Templates, and free Alpha access, Evagene.

Why teams look for alternatives to TrakGene

The most common reason is procurement. TrakGene does not publish list pricing; evaluation requires a sales conversation. For services that have already budgeted a platform and can run a procurement process, this is not an obstacle. For smaller teams, private counselling practices, or research groups who want to validate fit on a real case before opening a budget, a free or Alpha tier is often a practical necessity. Alternatives that publish pricing, run free tiers, or ship Alpha programmes remove the friction that TrakGene's enterprise sales motion introduces.

The second reason is modernising beyond FHIR. TrakGene's FHIR integration is strong, but AI-assisted interpretation, bring-your-own-key LLM support, Model Context Protocol agents, and programmatic pedigree tools are not among its publicly advertised features. Services whose 2026 roadmap includes AI-drafted summaries, AI agents that need to read and analyse pedigrees, or embeddable pedigree viewers often find it easier to build on a platform where those surfaces are first-class. A third reason is cancer-risk model breadth: TrakGene does not publicly advertise BOADICEA v6 or Tyrer-Cuzick v8, which services focused on breast and ovarian risk assessment may need.

Four alternatives worth evaluating

Phenotips

Phenotips is an enterprise-grade Genomic Health Record platform with Human Phenotype Ontology at its core. With 100,000+ records across 60+ countries per its homepage, it is a major player in institutional clinical genetics, particularly for undiagnosed rare disease services and phenotype-driven gene suggestion.

Where Phenotips fits as a TrakGene alternative: services whose workflow is HPO-first rare disease diagnostics rather than pedigree-first clinical genetics. Where it falls short: Phenotips and TrakGene share the enterprise sales-led procurement model, so Phenotips does not solve the pricing-opacity problem. If the thing that matters about your TrakGene evaluation is HPO depth, Phenotips is the stronger candidate. See our Phenotips vs Evagene article for detail.

FamGenix

FamGenix stands out for simultaneous coverage of BOADICEA v6, Tyrer-Cuzick v8, Gail, Claus, and QRISK3 — a combination matched by few products. It offers a free Individual tier and tiered pricing that removes enterprise procurement friction. For services whose practice is dominated by hereditary cancer risk assessment, it is a strong alternative.

Where FamGenix falls short relative to TrakGene: it is not positioned as a broad clinical genetics platform with FHIR-first EHR integration. If your service uses TrakGene for cardiac genetics, reproductive genetics, or integrated cohort work, FamGenix is likely narrower than you need.

Progeny

Progeny is among the longest-established clinical pedigree vendors (its product history reaches back to 1996) and has a real footprint in institutional clinical genetics. Its core strength is longevity, proven clinical deployments, and a mature feature set.

Where Progeny fits: institutions that want continuity with an established enterprise vendor and that value track record heavily. Where it falls short: third-party reports cite rising pricing over recent renewal cycles and an architectural heritage that predates modern cloud patterns. For teams choosing TrakGene over Progeny specifically because they wanted a modern architecture, Progeny is not a natural alternative; if the TrakGene evaluation concluded you want something even more enterprise-heavy, Progeny becomes worth considering.

Evagene

Evagene is a modern, browser-first, research- and education-grade pedigree-modelling platform with the same modern-architecture emphasis that makes TrakGene attractive, but a different shape. It covers gesture-driven pedigree drawing with NSGC/ISCN standard notation, a 230+ disease catalogue cross-referenced to ICD-10, OMIM, MONDO, Orphanet, and Disease Ontology (DOID) — five ontology systems, CURIE-searchable — cancer family-history models including Gail/BCRAT and an IBIS-style Tyrer-Cuzick approximation (a research/teaching approximation of the published Tyrer/Duffy/Cuzick 2004 algorithm, not the official IBIS binary) plus Claus, Couch, Frank, Manchester, NICE, Amsterdam II and revised Bethesda, the BayesMendel BRCAPRO/MMRpro/PancPRO models and an educational prostate-cancer model, Mendelian inheritance calculators for AD, AR, and XR conditions, a curated Human Phenotype Ontology (HPO) catalogue for attaching observed or excluded phenotype features with onset and severity (surfacing candidate associated genes as educational reference data — candidate associations only, not ranked likelihood or diagnosis), batch risk screening, a karyogram viewer, an educational/research relatedness module (pairwise kinship, inbreeding, Jacquard k0/k1/k2 identity, gene-dropping simulation), and consanguinity detection via Wright's coefficient.

What differentiates Evagene from TrakGene is the AI and platform surface. AI-assisted draft summaries for educational / research review use bring-your-own-key (BYOK) LLMs for Anthropic Claude and OpenAI GPT — your text flows to a provider you have already risk-assessed, not through a vendor-hosted model. Analysis Templates codify a house style for AI-drafted summaries. The catalogue carries 21 built-in published risk models (illustrative and for teaching), and the Related Concepts educational correlation graph surfaces 1,100+ curated associations as reference data (not risk analysis). The MCP server exposes 27 tools to Claude Desktop, Claude Code, and other MCP-compatible agents — so a user can ask their AI assistant to read, modify, or analyse a pedigree from inside their normal AI workspace — and the "Evagene Pedigree Builder" ChatGPT Custom GPT turns natural-language family history into a pedigree, while a guided Family History Questionnaire runs intake through to a pedigree. The REST API (scoped, rate-limited), HMAC-SHA256 webhooks, GA4GH Phenopackets v2 import/export (alongside GEDCOM 5.5.1 and the CanRisk/BOADICEA file), and the embeddable pedigree viewer (iframe/SVG/JS) cover the integration ground TrakGene addresses through FHIR, though with a more generic API-first shape.

Where Evagene falls short: it does not advertise the HL7 FHIR-native posture that is one of TrakGene's strongest positioning claims (FHIR support is available via the REST API rather than a first-class resource model). It does not bundle BOADICEA (it exports a ##CanRisk 2.0 file to canrisk.org for the canonical run), its Tyrer-Cuzick is an IBIS-style approximation rather than the official IBIS binary, and it does not run QRISK3. Its HPO catalogue supports educational phenotype documentation and candidate phenotype-to-gene reference data rather than enterprise phenotype-driven diagnostics. It is in Alpha and is not a medical device, with free access via waiting list; formal certifications should be confirmed at contract time. For teams evaluating TrakGene who want an AI-and-agent-first peer, Evagene is the intended fit.

Feature comparison matrix

Compiled from publicly available product pages as of June 2026. "—" means not publicly advertised.

How to choose

HPO-first rare disease diagnostics. Phenotips remains the strongest fit; TrakGene and Evagene are pedigree-first. Evagene now offers educational HPO phenotyping with candidate phenotype-to-gene reference data, but not Phenotips's diagnostic phenotype-driven depth.

Cancer-risk-dominated practice. FamGenix for official bundled BOADICEA v6 / Tyrer-Cuzick v8 / QRISK3 breadth; Evagene for Gail/BCRAT, an IBIS-style Tyrer-Cuzick approximation and the BayesMendel BRCAPRO/MMRpro/PancPRO models plus Mendelian, with a CanRisk/BOADICEA export bridge.

Deep FHIR-native EHR integration. TrakGene leads; Evagene covers the ground through a generic REST API rather than a FHIR resource model. If FHIR-as-the-data-model matters, TrakGene is the more direct fit.

Modern AI, agents, and programmability. Evagene — BYOK LLM, MCP server (27 tools), Analysis Templates, REST API, webhooks, Phenopackets v2 interoperability, an educational/research relatedness module, and an embeddable viewer. Start free on Alpha via the waiting list.

Frequently asked questions

Further reading

• Phenotips vs Evagene: a detailed comparison
• Progeny vs Evagene
• Clinical genetics pedigree tools: a field guide
• Hereditary cancer risk assessment
• Pedigree drawing software
• The Evagene platform layer (API, MCP, webhooks)